- Home
- EBS vs HUMA Comparison
EBS vs HUMA Comparison
Compare EBS & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- HUMA
- Stock Information
- Founded
- EBS 1998
- HUMA 2004
- Country
- EBS United States
- HUMA United States
- Employees
- EBS N/A
- HUMA N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- EBS Health Care
- HUMA Health Care
- Exchange
- EBS Nasdaq
- HUMA Nasdaq
- Market Cap
- EBS 359.3M
- HUMA 356.8M
- IPO Year
- EBS 2006
- HUMA N/A
- Fundamental
- Price
- EBS $9.23
- HUMA $1.58
- Analyst Decision
- EBS Strong Buy
- HUMA Strong Buy
- Analyst Count
- EBS 3
- HUMA 7
- Target Price
- EBS $14.33
- HUMA $11.93
- AVG Volume (30 Days)
- EBS 1.5M
- HUMA 6.2M
- Earning Date
- EBS 08-06-2025
- HUMA 08-11-2025
- Dividend Yield
- EBS N/A
- HUMA N/A
- EPS Growth
- EBS N/A
- HUMA N/A
- EPS
- EBS 2.53
- HUMA N/A
- Revenue
- EBS $851,600,000.00
- HUMA $818,000.00
- Revenue This Year
- EBS N/A
- HUMA N/A
- Revenue Next Year
- EBS $14.20
- HUMA $936.09
- P/E Ratio
- EBS $3.65
- HUMA N/A
- Revenue Growth
- EBS N/A
- HUMA N/A
- 52 Week Low
- EBS $4.02
- HUMA $1.15
- 52 Week High
- EBS $12.73
- HUMA $7.48
- Technical
- Relative Strength Index (RSI)
- EBS 68.42
- HUMA 34.06
- Support Level
- EBS $8.91
- HUMA $1.47
- Resistance Level
- EBS $9.43
- HUMA $2.02
- Average True Range (ATR)
- EBS 0.59
- HUMA 0.21
- MACD
- EBS 0.15
- HUMA -0.06
- Stochastic Oscillator
- EBS 88.89
- HUMA 8.56
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.